The current technology was developed as a topical wound dressing (medical device) that combines a moist alginate gel with the patented GAP573 peptide to give a ‘combination product’ (named AL-573) – this incorporates GAP573 in a moist alginate (AL) gel for slow release. The peptide can be manufactured at low cost in large volumes using synthetic peptide production methods. A prototype dressing has been produced and tested in a number of animal models with pleasing results. The enhanced wound-healing properties have been demonstrated in both rat and initial pig trials.
The Commercialisation Plan we have envisages two likely outcomes:
Our wound healing device provides clinicians with a product that will reduce the time to wound closure as well as reduce scarring. This device also has the potential to address persistent wounds that are unresponsive to other healing methods. The ultimate effect is that the length of treatment can be reduced and in turn clinician time and consumable usage per patient can be minimised. This efficiency gain is of course also of value to the health insurers. The value to the patient is common to the clinicians but also includes the scar reduction provided by our product.
provisional patents have been filed
Proof of Concept - Early prototype built